We are happy to announce that Gentian will be exhibiting at the AACC in Atlanta this September and at EUROMEDLAB in Munich at the end of November. We hope to see you there!
It has been quite an eventful quarter. Gentian has recently been listed on the Oslo Stock Exchange and has also been preparing to celebrate 20 years of innovating diagnostic efficiency.
If you have not yet had a chance to watch the American Kidney Fund Webinar Cystatin C: Its utility as an alternative for creatinine-based eGFR it is still available on YouTube and can be accessed through the link below. We have also launched a webinar on the role of plasma and serum calprotectin in the assessment of rheumatoid arthritis (RA), that we hope you will find interesting.
If you have any questions about Gentian or our products, please feel free to email us.
This year, Gentian is proudly celebrating 20 years of innovating diagnostic efficiency. Over the years, the company has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. With an open channel approach, Gentian products can be used without additional investment in instrumentation. Read our history here.
FREE WEBINAR: Cystatin C: Its utility as an alternative for creatinine-based eGFR
Gentian is a proud sponsor of the American Kidney Fund (AKF) webinar Cystatin C: Its utility as an alternative for creatinine-based eGFR. During this interactive webinar, a multidiscipline panel of experts will delve into the utility of the cystatin C test in diagnosing kidney disease. Measurement of serum cystatin C continue to gain a greater role in the estimation of kidney function, especially with growing scrutiny of the inclusion of race modifiers in the creatinine-based eGFR equation.
Take the opportunity to watch the AKF webinar about cystatin C as an alternative to creatinine based e-GFR.
WEBINAR: The role of calprotectin in RA
This webinar looks into the role plasma and serum calprotectin plays in the assessment of rheumatoid arthritis (RA). As calprotectin is a biomarker for neutrophil activation, it can be used to detect and assess the inflammation activity and severity.
The diagnosis of Pancreatic Exocrine Insufficiency (PEI) - BÜHLMANN fPELA® turbo
BÜHLMANN and Gentian celebrate the first successful year of the fecal turbidimetric pancreatic elastase assay; fPELA® turbo which is sold exclusively through our partner BÜHLMANN.
fPELA® turbo provides flexible and random access application on most clinical chemistry platforms, and offers an easy and faster way to receive required results for further evidence of a Pancreatic Exocrine Insufficiency. Read more about fPELA® turbo.
Gentian Diagnostics listed on the Oslo Stock Exchange
As the growing diagnostics market puts increasing pressure on clinical laboratory efficiency, many of the existing, clinically relevant biomarkers are still only available on slow and inefficient platforms. Gentian’s solution is to utilise PETIA (Particle-Enhanced Turbidimetric Immunoassays), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers.
You can learn more about Gentian by watching the bell ceremony and our company movie below.
FAQ: Plasma and serum calprotectin
In our Frequently Asked Questions about calprotectin series we will answer questions we often receive about plasma and serum calprotectin and the Gentian Calprotectin Immunoassay GCAL®. If you have any additional questions don't hesitate to contact us on firstname.lastname@example.org.